MWMichael A. Weitzner

Michael A. Weitzner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael A. Weitzner has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • THE FAMILY CAREGIVER OF THE OLDER CANCER PATIENT

    by Michael A. Weitzner, William E. Haley, Hongbin Chen


  • Borderline personality disorder and bone marrow transplantation: ethical considerations and review

    by Michael A. Weitzner, Frank Lehninger, Daniel Sullivan, Karen K. Fields

    Bone marrow transplantation (BMT) is rapidly becoming a part of conventional cancer treatment. However, it remains a ‘last‐ditch’ treatment option for patients who have exhausted other treatment modalities. Patients experience a significant amount of emotional distress during all stages of the BMT process. Patients with personality disorders experience even more emotional distress than average and their behavior is often detrimental to effective patient–staff interactions. A case of a borderline patient is presented with a discussion of the ethical issues involved in the evaluation of these patients and the determination of their appropriateness for transplant. Copyright © 1999 John Wiley & Sons, Ltd.


  • Psychosocial and Neuropsychiatric Aspects of Patients with Primary Brain Tumors

    by Michael A. Weitzner

    Primary brain tumors are increasing in incidence in the United States and are devastating to patients and families. Because brain tumors and their treatment primarily affect the brain, psychiatric and psychosocial impact is rather unique. As opposed to systemic effects of other tumors and treatment, brain tumors have a direct affect on brain functioning and therefore affect cognition, mood, and personality. In fact, patients undergo dramatic changes in mood and cognition, showing specific in impairments in functioning. These impairments get translated into disabilities when a patient's daily functioning is impaired and may become a handicap when viewed in the context of quality of life (QOL). This article describes observed neuropsychiatric syndromes, including the apathy syndrome, and neurocognitive affects of brain tumors and their treatment. The neuropsychiatric and neurocognitive issues are discussed in the context of QOL and psychosocial and cognitive interventions available for this patient population.


  • The Caregiver Quality of Life Index–Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer

    by M. A. Weitzner, P. B. Jacobsen, H. Wagner, J. Friedland, C. Cox

    Family caregivers have become increasingly responsible for providing home care for cancer patients. Research has documented the distress of family caregivers; however, little has been done to...


  • The Impact of Pituitary Disease on the Family Caregiver and Overall Family Functioning

    by Michael Weitzner, Robert Knutzen

    Chronic medical illness not only affects the patient but the entire family. The family system undergoes a tremendous change in focus during the acute illness, with members marshaling their resources to help the ill member. This inward focus is costly, producing profound stress. Often, family communication styles change to protect the family system and prior functioning. When the stress of caring for an ill member becomes chronic, as is seen in pituitary disease, the initially adaptive changes in family functioning may become problematic even in those families with previously healthy coping. Those families with previously less healthy functioning become even more dysfunctional. Each family identifies a caregiver for their ill member. This caregiver also experiences significant stress related to caregiving demands. Caregiver adaptation to the stress depends on how the stress is perceived, as well as the caregiver’s coping patterns and availability of and satisfaction with social support. These elements comprise a stress process model of caregiving, which has been well-validated in dementia caregiving research. Although the majority of research has focused on dementia and cancer caregiving, identified issues have applicability to caregiving and family issues related to pituitary disease. This report will review: (1) the field of caregiving research, focusing on a stress process model; (2) those issues identified in prior caregiving research which have applicability in caregiving for patients with pituitary disease; (3) stresses on the family system; (4) assessment of family functioning, and (5) interventions for caregivers and areas for future research.


  • Neuropsychiatry and Pituitary Disease: An Overview

    by Michael Weitzner

    It has been recognized for some time that psychiatric symptoms, such as depression, anxiety, and behavioral alterations, may occur in patients who have pituitary disease. From other research focused on endocrine abnormalities seen in patients with psychiatric illness, it is understood that there is a significant interrelationship between the endocrine system and mental health. More recent research focusing on neural circuits in the brain and the impact of alterations in neurotransmission and neurohormonal modulation has shown that the prefrontal cortex can be affected by perturbations in functioning occurring in distant sites. Such is the situation with the hypothalamic-pituitary axis. Through its rich connections with other limbic structures, the hypothalamic-pituitary axis may affect the behavioral control exerted by the prefrontal cortex, causing mood and personality alterations. In the more severe cases, an apathy syndrome may develop which must be carefully differentiated from depression and other cognitive disorders. This report will review: (1) the neuroanatomical components that cause the behavioral changes observed in many patients with pituitary disease; (2) the current concept of apathy syndrome; (3) the differentiation of apathy syndrome from major depression; (4) the underlying neurobiology of apathy, and (5) potential treatments.